Tag: attorney

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company’s stock dropped. 

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

AUGA group, AB entity under restructuring (code 126264360, registered office at Konstitucijos pr. 21C, Vilnius, hereinafter referred to as the “Company”), by the initiative and decision of the Board, is convening a General meeting of shareholders on August 12, 2025, at 10:00 a.m., where the Company’s shareholders will vote on the approval of the Company’s draft restructuring plan, hereinafter referred to as the “Meeting”.

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Fortrea’s business, operations, and prospects, including allegations that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the transition services agreements; (iii) as a result, Fortrea’s previously announced EBITDA targets for 2025 were inflated; and (iv) accordingly, the viability of the Company’s post-Spin-Off business model, as well as its business and/or financial prospects, were overstated.

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk.

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Broadmark Realty Capital Inc. (“Broadmark” or “the Company”) (NYSE: BRMK), Ready Capital Corporation ("Ready Capital") (NYSE: RC), and certain officers.

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. (“DoubleVerify” or “the Company”) (NYSE: DV) and certain of its officers.